Variation in costs due to virtual switching from free- to fixed-triple LABA/LAMA/ICS combinations among COPD patients: an analysis using a primary care database

References

• Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• Belleudi V, Di Martino M, Cascini S, OUTPUL Study Group, et al. The impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approach. Pharmacoepidemiol Drug Saf. 2016;25(11):1295–1304.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Bianchini E, Onder G, et al. Poor adherence to chronic obstructive pulmonary disease medications in primary care: role of age, disease burden and polypharmacy. Geriatr Gerontol Int. 2017;17(12):2500–2506.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet (London, England. 2016;388(10048):963–973.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. COPD. 2015;10:2207–2217.
   Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
   PubMed Web of Science ®Google Scholar
• Kirchmayer U, Cascini S, Agabiti N, OUTPUL Study Group, et al. One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study. Pharmacoepidemiol Drug Saf. 2016;25(5):578–589.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Zucchelli A, Bianchini E, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir Med. 2019;154:12–17.
   PubMed Web of Science ®Google Scholar
• Lapi F, Marconi E, Pecchioli S, et al. Reduced effectiveness among β-lactam antibiotics: a population-based cohort study in primary care in Italy. J Antimicrob Chemother. 2021;76(8):2186–2194.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Zucchelli A, Bianchini E, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir Med. 2019;154:12–17.
   PubMed Web of Science ®Google Scholar
• farmaci.agenziafarmaco.gov.it/bancadatifarmaci [internet]. Roma; [cited 2022 July 1] Available from: http://https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/
   Google Scholar
• Lists of class A and class H medicinal products | Italian Medicines Agency; 2022 [cited 2022 July 29]. Available from: https://www.aifa.gov.it/en/liste-farmaci-a-h.
   Google Scholar
• Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111:47–53.
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (Agenzia Italiana del Farmaco) Nota 99. AIFA – NOTA 99 [internet]. Roma (IT): Agenzia Italiana del Farmaco; 2022 [cited 2022 July 1]. Available from: https://www.aifa.gov.it/nota-99
   Google Scholar
• Maio S, Baldacci S, Martini F, COMODHES Study Group, et al. COPD management according to old and new GOLD guidelines: an observational study with italian general practitioners. Curr Med Res Opin. 2014;30(6):1033–1042.
   PubMed Web of Science ®Google Scholar
• Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2021. [cited 2022 July 1]. Available from: https://goldcopd.org/
   Google Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632.
   PubMed Web of Science ®Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):00480–2020.
   PubMedGoogle Scholar
• Mauskopf J, Earnshaw SR, Brogan A, et al. Budget-impact analysis of health care interventions. 1st ed. New York (NY): Springer; 2017.
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices–budget impact analysis. Value Health. 2007;10(5):336–347.
   PubMed Web of Science ®Google Scholar
• Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report–part I. Value Health. 2009;12(8):1044–1052.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report–part III. Value Health. 2009;12(8):1062–1073.
   PubMed Web of Science ®Google Scholar